SEITZ CHRISTIAN
No ORCID on file
· 18 papers in corpus
other
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
other
2011
The pharmaceutical preparation for treating endometriosis contains at least 28, preferably 30, daily dose units, each of which contain dienogest, cyproterone acetate, or chlormadinone acetate at a daily dose that is at most twice that requi…
other
2010
Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…
2010
2010
2009
2009
other
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17Î+--cyanomethyl-17Ã -hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacet…
other
2009
A combination of an anti-androgenic gestagen at a daily dose of from an ovulation-inhibiting dose up to at most twice the ovulation-inhibiting dose and from 0.1 to 10 mg of (6S)-5-methyltetrahydrofolate are used to produce a pharmaceutical …
other
2009
Use of gestagen in combination with (6S)-5-methyltetrahydrofolate for the production of a pharmaceutical preparation (I) for the therapy of endometriosis with simultaneous reduction of therapy side-effects, preferably negative effects on bo…
other
2009
Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…
2009
other
2009
Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…
other
2008
Pharmaceutical composition comprises a gestagen with anti-androgenic activity at a daily dosage, which is no more than two times the dosage required to suppress ovulation, together with one more adjuvants/carriers. The composition has lack …
other
2008
The pharmaceutical preparation for treating endometriosis contains at least 28, preferably 30, daily dose units, each of which contain dienogest, cyproterone acetate, or chlormadinone acetate at a daily dose that is at most twice that requi…
2008
other
2008
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
other
2008
A pharmaceutical composition for the treatment of endometriosis without l oss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17.alpha.-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienoges t), cyproter…